{"title":"Questions and Answers August 2022","authors":"Margareth R. C. Marques, M. Liddell","doi":"10.14227/dt290322p174","DOIUrl":"https://doi.org/10.14227/dt290322p174","url":null,"abstract":"","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66814014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natasha Stella Tibon, R. Allada, Sudhakar Vakkala, Prakash Muthudoss, S. Shahnawaz
In the case of most phosphate-binding agents, in vitro phosphate-binding studies are essential for establishing bioequivalence between generic and reference drug formulations. Traditionally, an incubator shaker is used to conduct phosphate-binding studies, but this method is limited by manual sample collection and associated variability. This study aims to evaluate an automatic sampling method using a dissolution tester as an alternative to incubator shakers. Kinetic phosphate-binding studies of sevelamer carbonate tablets (test and reference formulations) were performed using an incubator shaker and USP dissolution apparatus 2. The results from both methods were compared. Though both formulations were equivalent in terms of the phosphate-binding capacity in both methods, the automatic sampling method using the dissolution apparatus had less variability than the manual sampling method using the incubator shaker. Thus, the dissolution apparatus is preferred for bioequivalence and interchangeability studies of sevelamer carbonate tablets.
{"title":"Comparison of In Vitro Phosphate-Binding Studies of Sevelamer Carbonate Using Incubator Shaker and USP Dissolution Apparatus II","authors":"Natasha Stella Tibon, R. Allada, Sudhakar Vakkala, Prakash Muthudoss, S. Shahnawaz","doi":"10.14227/dt290222p78","DOIUrl":"https://doi.org/10.14227/dt290222p78","url":null,"abstract":"In the case of most phosphate-binding agents, in vitro phosphate-binding studies are essential for establishing bioequivalence between generic and reference drug formulations. Traditionally, an incubator shaker is used to conduct phosphate-binding studies, but this method is limited by manual sample collection and associated variability. This study aims to evaluate an automatic sampling method using a dissolution tester as an alternative to incubator shakers. Kinetic phosphate-binding studies of sevelamer carbonate tablets (test and reference formulations) were performed using an incubator shaker and USP dissolution apparatus 2. The results from both methods were compared. Though both formulations were equivalent in terms of the phosphate-binding capacity in both methods, the automatic sampling method using the dissolution apparatus had less variability than the manual sampling method using the incubator shaker. Thus, the dissolution apparatus is preferred for bioequivalence and interchangeability studies of sevelamer carbonate tablets.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66813293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The purpose of this paper is to provide an overview of the activities of the USP Expert Panel on New Advancements in Product Performance testing.
本文的目的是概述USP专家小组在产品性能测试方面的新进展。
{"title":"Overview of the Activities of the USP Expert Panel on New Advancements in Product Performance Testing","authors":"R. Skwierczynski, V. Gray, James De Muth","doi":"10.14227/dt290322p122","DOIUrl":"https://doi.org/10.14227/dt290322p122","url":null,"abstract":"The purpose of this paper is to provide an overview of the activities of the USP Expert Panel on New Advancements in Product Performance testing.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66813443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Gray, Andreas M. Abend, M. Alasandro, P. Armenante, Tessa M. Carducci, B. Crist, Fashen Li, Xujin Lu, Margareth R. C. Marques, Kevin Moore, B. Nickerson
– dissolution
—溶解
{"title":"Dissolution Best Practices and International Harmonization - AAPS Workshop Report","authors":"V. Gray, Andreas M. Abend, M. Alasandro, P. Armenante, Tessa M. Carducci, B. Crist, Fashen Li, Xujin Lu, Margareth R. C. Marques, Kevin Moore, B. Nickerson","doi":"10.14227/dt290422p230","DOIUrl":"https://doi.org/10.14227/dt290422p230","url":null,"abstract":"– dissolution","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66813732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Alwadi, Ghosoun M. Arafeh, Mohammad S. Almehlesi, H. Maswadeh, I. M. Salman, O. Ameer
Acetaminophen is a widely used oral analgesic and antipyretic medication; however, quality control parameters may differ across various brands. The aim of the present study was to evaluate and compare critical quality attributes, including in-vitro dissolution characteristics, of five acetaminophen tablet brands (labeled A–E) from the Saudi market and determine their pharmaceutical equivalence. All brands were tested for conformity with the United States Pharmacopoeia (USP) standards, through evaluation of weight variation, hardness, friability, disintegration, and dissolution. Dissolution profiles were compared using model-dependent and independent approaches relative to the innovator brand A (Panadol). All tested brands passed the weight variation and friability tests with deviations of less than 5% from the average weight and less than 1% weight loss, respectively, with the exception of brand C showing relatively higher friability (1.13%). All brands displayed variable disintegration times; however, all were compliant with USP specifications. All studied tablets released less than 80% of the drug within 30 minutes; however, brands B and C had lower drug release rates, area under the curve (AUC), and dissolution efficiency (DE) compared with the innovator. Brand E, on the other hand, had a higher drug release rate, AUC, DE, and mean dissolution time (MDT), and thus was pharmaceutically inequivalent to the innovator. All tested brands exhibited a non swellable matrix diffusion-controlled dissolution as assessed by the Korsmeyer-Peppas model of drug-release kinetics. In conclusion, all acetaminophen brands were able to pass USP specifications to justify interchangeability. Minor variations in in-vitro dissolution characteristics could reflect inherent manufacturing compounding differences.
{"title":"Comparative Analysis of Commercially Available Acetaminophen Tablets in Saudi Arabia","authors":"A. Alwadi, Ghosoun M. Arafeh, Mohammad S. Almehlesi, H. Maswadeh, I. M. Salman, O. Ameer","doi":"10.14227/dt290322pgc2","DOIUrl":"https://doi.org/10.14227/dt290322pgc2","url":null,"abstract":"Acetaminophen is a widely used oral analgesic and antipyretic medication; however, quality control parameters may differ across various brands. The aim of the present study was to evaluate and compare critical quality attributes, including in-vitro dissolution characteristics, of five acetaminophen tablet brands (labeled A–E) from the Saudi market and determine their pharmaceutical equivalence. All brands were tested for conformity with the United States Pharmacopoeia (USP) standards, through evaluation of weight variation, hardness, friability, disintegration, and dissolution. Dissolution profiles were compared using model-dependent and independent approaches relative to the innovator brand A (Panadol). All tested brands passed the weight variation and friability tests with deviations of less than 5% from the average weight and less than 1% weight loss, respectively, with the exception of brand C showing relatively higher friability (1.13%). All brands displayed variable disintegration times; however, all were compliant with USP specifications. All studied tablets released less than 80% of the drug within 30 minutes; however, brands B and C had lower drug release rates, area under the curve (AUC), and dissolution efficiency (DE) compared with the innovator. Brand E, on the other hand, had a higher drug release rate, AUC, DE, and mean dissolution time (MDT), and thus was pharmaceutically inequivalent to the innovator. All tested brands exhibited a non swellable matrix diffusion-controlled dissolution as assessed by the Korsmeyer-Peppas model of drug-release kinetics. In conclusion, all acetaminophen brands were able to pass USP specifications to justify interchangeability. Minor variations in in-vitro dissolution characteristics could reflect inherent manufacturing compounding differences.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"5 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66814083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Chumpitaz-Cerrate, L. Moreno-Exebio, E. Ruiz-Ramírez, César Franco-Quino, M. Flores-Rodríguez, L. Chávez-Rimache
This study aimed to determine the therapeutic equivalence of four multi-source drugs containing moxifloxacin (400 mg tablets) in vitro studies to establish their interchangeability with the reference product. Four multi-source products were acquired in pharmaceutical establishments in metropolitan Lima, each from different manufacturing sites (two products from India, one from Brazil, and one from Peru). The reference product was Avelox (400 mg) coated tablets (Bayer AG, Germany). Quality control and dissolution profile tests were performed. For dissolution tests, a validated ultraviolet-visible spectrophotometry method was used to determine the percentage of drug released. The similarity factor (f2) analysis was used to establish therapeutic equivalence of the drug release curves. The dissolution rates were considered equivalent if the values of f2 were between 50 and 100. Concerning the quality control tests, the moxifloxacin content was 98.5% in the reference product and 97.1–100.0% in the multisource products. Three out of four multi-source products passed the f2 test at pH 1.2. Therefore, there is at least one moxifloxacin multi-source product circulating in Peru, manufactured in India, that does not is not interchangeable with the reference product.
{"title":"Therapeutic Equivalence Evaluated Through In Vitro Studies of Multi-Source Drugs: A Moxifloxacin Case Study in Lima, Peru","authors":"V. Chumpitaz-Cerrate, L. Moreno-Exebio, E. Ruiz-Ramírez, César Franco-Quino, M. Flores-Rodríguez, L. Chávez-Rimache","doi":"10.14227/dt290122pgc1","DOIUrl":"https://doi.org/10.14227/dt290122pgc1","url":null,"abstract":"This study aimed to determine the therapeutic equivalence of four multi-source drugs containing moxifloxacin (400 mg tablets) in vitro studies to establish their interchangeability with the reference product. Four multi-source products were acquired in pharmaceutical establishments in metropolitan Lima, each from different manufacturing sites (two products from India, one from Brazil, and one from Peru). The reference product was Avelox (400 mg) coated tablets (Bayer AG, Germany). Quality control and dissolution profile tests were performed. For dissolution tests, a validated ultraviolet-visible spectrophotometry method was used to determine the percentage of drug released. The similarity factor (f2) analysis was used to establish therapeutic equivalence of the drug release curves. The dissolution rates were considered equivalent if the values of f2 were between 50 and 100. Concerning the quality control tests, the moxifloxacin content was 98.5% in the reference product and 97.1–100.0% in the multisource products. Three out of four multi-source products passed the f2 test at pH 1.2. Therefore, there is at least one moxifloxacin multi-source product circulating in Peru, manufactured in India, that does not is not interchangeable with the reference product.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66813240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Book Review: “Analytical Testing for the Pharmaceutical GMP Laboratory”","authors":"G. P. Martin","doi":"10.14227/dt290422p228","DOIUrl":"https://doi.org/10.14227/dt290422p228","url":null,"abstract":"","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66813688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Doaa R. Adam, Nuran Al Rayes, Raghad Fatoum, Ghosoun M. Arafeh, T. Adam, A. Kola-Mustapha
The objective of this study was to evaluate the physicochemical quality control parameters and pharmaceutical equivalence of amlodipine besylate generic tablets and capsules with the innovator brands (Norvasc and Amlor, respectively) available in Riyadh, Saudi Arabia. Five brands of amlodipine besylate tablets and capsules (5 mg) were compared via quality control tests according to the United States Pharmacopoeia (i.e., hardness, thickness, diameter, weight variation, uniformity of dosage content, friability, disintegration, dissolution by ultraviolet spectrophotometry, and Fourier-transform infrared spectroscopy (FTIR)). All selected brands were found to comply with USP-NF specifications concerning weight variation, hardness, friability, disintegration time, FTIR, and drug content analysis. The dissolution profiles for all products satisfied the USP-NF specifications. Regarding, model-dependent data, all the tested brands followed the Higuchi model of release. Using the model-independent approach (i.e., similarity factor analysis), all products were considered similar except for one generic product (ABC-3). All brands had no significant difference in mean dissolution efficiency compared to the innovator, except ABC-3.
{"title":"Comparative Evaluation of Amlodipine Besylate Generic Tablet and Capsule Brands in Riyadh, Saudi Arabia","authors":"Doaa R. Adam, Nuran Al Rayes, Raghad Fatoum, Ghosoun M. Arafeh, T. Adam, A. Kola-Mustapha","doi":"10.14227/dt290422pgc2","DOIUrl":"https://doi.org/10.14227/dt290422pgc2","url":null,"abstract":"The objective of this study was to evaluate the physicochemical quality control parameters and pharmaceutical equivalence of amlodipine besylate generic tablets and capsules with the innovator brands (Norvasc and Amlor, respectively) available in Riyadh, Saudi Arabia. Five brands of amlodipine besylate tablets and capsules (5 mg) were compared via quality control tests according to the United States Pharmacopoeia (i.e., hardness, thickness, diameter, weight variation, uniformity of dosage content, friability, disintegration, dissolution by ultraviolet spectrophotometry, and Fourier-transform infrared spectroscopy (FTIR)). All selected brands were found to comply with USP-NF specifications concerning weight variation, hardness, friability, disintegration time, FTIR, and drug content analysis. The dissolution profiles for all products satisfied the USP-NF specifications. Regarding, model-dependent data, all the tested brands followed the Higuchi model of release. Using the model-independent approach (i.e., similarity factor analysis), all products were considered similar except for one generic product (ABC-3). All brands had no significant difference in mean dissolution efficiency compared to the innovator, except ABC-3.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66813880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María R. Bendezú, Jorge A. García, H. Chávez, A. M. Muñoz, J. Jáuregui, Miguel Mucha, R. Losno, María Saravia, Angel T. Alvarado
Acetylsalicylic acid is one of the most prescribed medications in the world. It is used for prevention of acute myocardial infarction, colorectal cancer, antipyretic, and as an analgesic. This study aimed to investigate the in vitro bioequivalence of three formulations of acetylsalicylic acid, simulating physiological conditions of the dissolution medium, and analyzing its possible implication for public health. A spectrophotometric method for the quantification of acetylsalicylic acid at 265 nm was used. The dissolution test was performed using a USP apparatus 2 (paddle) with 900 mL of medium at 37 ± 0.5 °C and 75 rpm. At pH 4.5 and 6.8, the three formulations did not meet the criteria of very fast or fast dissolution (85% in ≤ 15 or 30 min, respectively). Generic A has a similarity factor ( f 2 ) of 50 at pH 4.5 and 80.7 at pH 6.8; generic C f 2 values were 31.2 at pH 4.5 and 72.4 at pH 6.8. Generic B did not meet the acceptance range of the similarity factor (50 − 100) at pH 4.5 and 6.8. For all products tested, the dissolution efficiency was greater than 79%, and the mean dissolution time was 5.5–15.9 min. Based on the in vitro dissolution results, Generic A is bioequivalent with the innovator, whereas generics B and C are not. However, the dissolution profiles of generics A and C are similar to the innovator at pH 6.8, which is the appropriate dissolution medium for this drug.
{"title":"In Vitro Bioequivalence of Acetylsalicylic Acid and Implications in Public Health","authors":"María R. Bendezú, Jorge A. García, H. Chávez, A. M. Muñoz, J. Jáuregui, Miguel Mucha, R. Losno, María Saravia, Angel T. Alvarado","doi":"10.14227/dt290322pgc1","DOIUrl":"https://doi.org/10.14227/dt290322pgc1","url":null,"abstract":"Acetylsalicylic acid is one of the most prescribed medications in the world. It is used for prevention of acute myocardial infarction, colorectal cancer, antipyretic, and as an analgesic. This study aimed to investigate the in vitro bioequivalence of three formulations of acetylsalicylic acid, simulating physiological conditions of the dissolution medium, and analyzing its possible implication for public health. A spectrophotometric method for the quantification of acetylsalicylic acid at 265 nm was used. The dissolution test was performed using a USP apparatus 2 (paddle) with 900 mL of medium at 37 ± 0.5 °C and 75 rpm. At pH 4.5 and 6.8, the three formulations did not meet the criteria of very fast or fast dissolution (85% in ≤ 15 or 30 min, respectively). Generic A has a similarity factor ( f 2 ) of 50 at pH 4.5 and 80.7 at pH 6.8; generic C f 2 values were 31.2 at pH 4.5 and 72.4 at pH 6.8. Generic B did not meet the acceptance range of the similarity factor (50 − 100) at pH 4.5 and 6.8. For all products tested, the dissolution efficiency was greater than 79%, and the mean dissolution time was 5.5–15.9 min. Based on the in vitro dissolution results, Generic A is bioequivalent with the innovator, whereas generics B and C are not. However, the dissolution profiles of generics A and C are similar to the innovator at pH 6.8, which is the appropriate dissolution medium for this drug.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66814023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Gray, D. Diaz, J. Dressman, Y. Tsume, N. Fotaki
Rapid Fire Moderated by Mamta Kapoor (FDA), the first speaker was Heather Boyce (FDA), with a talk titled “Establishing Bioequivalence for ‘Additional Strengths’ of Oral Modified-Release Drug Products’. She described the FDA guidance, Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA, that includes recommendations outlining approaches for establishing bioequivalence of additional strengths of a proposed modified release (MR) drug product for oral administration. Through two case studies of Bupropion HCl extended-release (ER) tablets and Venlafaxine HCl ER tablets, she illustrated that the FDA’s current thinking places less emphasis on compositional proportionality requirements than prior years. Whether a product is considered compositional or not, additional justification related to the proposed product release mechanism and excipient levels should be provided to use alternative methods to support and strengthen the bioequivalence study.
{"title":"Highlights from the 2020 AAPS 360 Annual Meeting","authors":"V. Gray, D. Diaz, J. Dressman, Y. Tsume, N. Fotaki","doi":"10.14227/DT280221P36","DOIUrl":"https://doi.org/10.14227/DT280221P36","url":null,"abstract":"Rapid Fire Moderated by Mamta Kapoor (FDA), the first speaker was Heather Boyce (FDA), with a talk titled “Establishing Bioequivalence for ‘Additional Strengths’ of Oral Modified-Release Drug Products’. She described the FDA guidance, Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA, that includes recommendations outlining approaches for establishing bioequivalence of additional strengths of a proposed modified release (MR) drug product for oral administration. Through two case studies of Bupropion HCl extended-release (ER) tablets and Venlafaxine HCl ER tablets, she illustrated that the FDA’s current thinking places less emphasis on compositional proportionality requirements than prior years. Whether a product is considered compositional or not, additional justification related to the proposed product release mechanism and excipient levels should be provided to use alternative methods to support and strengthen the bioequivalence study.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66813004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：